The University of Southampton
University of Southampton Institutional Repository

Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse

Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse
Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse
Deregulation of the RAS-RAF-MEK-ERK signalling cascade, often caused by activating mutations in the RAS family of G-proteins, is a recurrent event in haematological malignancies including childhood acute lymphoblastic leukemia (ALL). However, deregulation of this pathway can also arise from mutational events in genes encoding other proteins which impact on this pathway including FLT3, PTPN11 and BRAF and such mutations have recently been identified in childhood ALL. The combined incidence of mutations in these genes, along with the RAS family is not known, but may be significant.
A comprehensive mutational screen of key exons of NRAS, KRAS2, FLT3, PTPN11 and BRAF was performed in 86 diagnostic and 49 relapse childhood ALL samples using denaturing high performance liquid chromatography (DHPLC) and direct sequencing and/or PCR product cloning. Using wild type cells spiked with cell lines bearing known mutations, the sensitivity of this screening assay was shown to be between 12–25%.
At diagnosis the combined mutation incidence was 35% (30 from 86) made up of NRAS (n=16), KRAS2 (n=15), FLT3 (n=3), PTPN11 (n=2), with 4 patients having more than one mutation. At relapse, 25 % (12 from 49) of cases showed mutations and included NRAS (n=4), KRAS2 (n=6), FLT3 (n=1) and PTPN11 (n=1). No mutations were identified in BRAF. While at relapse the mutated blasts were always the predominant population, in 7 of the 30 diagnostic cases, only a minor subpopulation of blasts housed the mutation and included all of the FLT3 insertion/deletion mutants. In 2 relapsed cases with mutations in KRAS2, mutations were not detectable by DHPLC in the matched diagnostic samples but were apparent at low level when a more sensitive allele-specific PCR was employed (assay sensitivity between 0.1–1%).
These data reveal a significant role of RAS-RAF-MEK-ERK pathway deregulation in leukemogenesis and implicate the pathway in some patients with progression to relapse. In addition, they highlight the genetic heterogeneity of leukemic blasts at diagnosis compared to those at relapse suggesting that clonal selection occurs in response to drug exposure. Inhibitors of the pathway, which are currently undergoing clinical trial, may be a novel therapeutic option for a significant proportion of children with relapsed ALL.
childhood, time, gene, acute lymphoblastic leukemia, mutation, leukemia, genes, diagnosis
0006-4971
160B-161B
Irving, Julie
d6d4ae90-4a64-45f6-8c2a-360cf71cb999
Minto, Lynne
4ffd3f1d-ffba-40d5-bb99-c1098dcb494b
Matheson, Elizabeth
1794dbcb-52c3-4c16-8984-88bb06ac7322
Case, Marian
81f27d29-1d48-442f-a054-4d40f1abac47
Bailey, Simon
0841f9a7-dfe7-48dd-9e97-5075ec6cc035
Bown, Nick
86f5aed2-bbf4-42de-ab91-ff6408c721e7
Hassan, Rosline
85e3f04d-985b-49fd-b585-24ebc9f4879c
Harrison, Christine
c509c372-2275-44cd-ad07-296a289d6634
Hall, Andrew
d88caf4d-4d33-49fe-a7de-d837dee8a1d9
Irving, Julie
d6d4ae90-4a64-45f6-8c2a-360cf71cb999
Minto, Lynne
4ffd3f1d-ffba-40d5-bb99-c1098dcb494b
Matheson, Elizabeth
1794dbcb-52c3-4c16-8984-88bb06ac7322
Case, Marian
81f27d29-1d48-442f-a054-4d40f1abac47
Bailey, Simon
0841f9a7-dfe7-48dd-9e97-5075ec6cc035
Bown, Nick
86f5aed2-bbf4-42de-ab91-ff6408c721e7
Hassan, Rosline
85e3f04d-985b-49fd-b585-24ebc9f4879c
Harrison, Christine
c509c372-2275-44cd-ad07-296a289d6634
Hall, Andrew
d88caf4d-4d33-49fe-a7de-d837dee8a1d9

Irving, Julie, Minto, Lynne, Matheson, Elizabeth, Case, Marian, Bailey, Simon, Bown, Nick, Hassan, Rosline, Harrison, Christine and Hall, Andrew (2006) Mutation in genes impacting on the RAS-RAF-MEK-ERK pathway are found at high incidence in childhood acute lymphoblastic leukemia at both diagnosis and at relapse. Blood, 108 (11), 160B-161B.

Record type: Article

Abstract

Deregulation of the RAS-RAF-MEK-ERK signalling cascade, often caused by activating mutations in the RAS family of G-proteins, is a recurrent event in haematological malignancies including childhood acute lymphoblastic leukemia (ALL). However, deregulation of this pathway can also arise from mutational events in genes encoding other proteins which impact on this pathway including FLT3, PTPN11 and BRAF and such mutations have recently been identified in childhood ALL. The combined incidence of mutations in these genes, along with the RAS family is not known, but may be significant.
A comprehensive mutational screen of key exons of NRAS, KRAS2, FLT3, PTPN11 and BRAF was performed in 86 diagnostic and 49 relapse childhood ALL samples using denaturing high performance liquid chromatography (DHPLC) and direct sequencing and/or PCR product cloning. Using wild type cells spiked with cell lines bearing known mutations, the sensitivity of this screening assay was shown to be between 12–25%.
At diagnosis the combined mutation incidence was 35% (30 from 86) made up of NRAS (n=16), KRAS2 (n=15), FLT3 (n=3), PTPN11 (n=2), with 4 patients having more than one mutation. At relapse, 25 % (12 from 49) of cases showed mutations and included NRAS (n=4), KRAS2 (n=6), FLT3 (n=1) and PTPN11 (n=1). No mutations were identified in BRAF. While at relapse the mutated blasts were always the predominant population, in 7 of the 30 diagnostic cases, only a minor subpopulation of blasts housed the mutation and included all of the FLT3 insertion/deletion mutants. In 2 relapsed cases with mutations in KRAS2, mutations were not detectable by DHPLC in the matched diagnostic samples but were apparent at low level when a more sensitive allele-specific PCR was employed (assay sensitivity between 0.1–1%).
These data reveal a significant role of RAS-RAF-MEK-ERK pathway deregulation in leukemogenesis and implicate the pathway in some patients with progression to relapse. In addition, they highlight the genetic heterogeneity of leukemic blasts at diagnosis compared to those at relapse suggesting that clonal selection occurs in response to drug exposure. Inhibitors of the pathway, which are currently undergoing clinical trial, may be a novel therapeutic option for a significant proportion of children with relapsed ALL.

This record has no associated files available for download.

More information

Published date: 16 November 2006
Additional Information: ASH Annual Meeting Abstracts, Abstracts Not Selected for Presentation. Abstract 4328.
Keywords: childhood, time, gene, acute lymphoblastic leukemia, mutation, leukemia, genes, diagnosis

Identifiers

Local EPrints ID: 62795
URI: http://eprints.soton.ac.uk/id/eprint/62795
ISSN: 0006-4971
PURE UUID: b1f485bd-93ec-40a8-9895-4c3ba1347ab8

Catalogue record

Date deposited: 10 Nov 2008
Last modified: 22 Jul 2022 21:17

Export record

Contributors

Author: Julie Irving
Author: Lynne Minto
Author: Elizabeth Matheson
Author: Marian Case
Author: Simon Bailey
Author: Nick Bown
Author: Rosline Hassan
Author: Christine Harrison
Author: Andrew Hall

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×